NightstaRx Boasts Advantage Over Spark In Inherited Retinal Disease

Spun out from the University of Oxford, new born NightstarRx is finding its feet in the biopharma field and has closed a $35m series B funding, with which it will boost its inherited retinal disease pipeline.